Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease
NCT01315795
·
clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
COMPLETED
Status
59
Enrollment
OTHER
Sponsor class
Conditions
Polycystic Liver Disease
Interventions
DRUG:
Lanreotide Autogel 90 mg and 120 mg
Sponsor
Universitaire Ziekenhuizen KU Leuven
Collaborators
[object Object]